| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Evogene Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪1.96 |
| 52 Week High | ₪10.40 |
| 52 Week Low | ₪1.70 |
| Beta | 1.08 |
| 11 Month Change | -23.88% |
| 3 Month Change | -52.77% |
| 1 Year Change | -69.02% |
| 33 Year Change | -91.55% |
| 5 Year Change | -86.76% |
| Change since IPO | -85.48% |
Recent News & Updates
Recent updates
Evogene unit files for EPA approval of bio-fungicide LAV.311 for fruit rots
Oct 12Evogene unit launches 2nd-gen medical cannabis products in Israel
Sep 21Lavie Bio appoints Guri Oron as CEO
Sep 14Evogene GAAP EPS of -$0.42 misses by $0.23, revenue of $0.55M beats by $0.33M
Aug 31Evogene regains compliance with Nasdaq's minimum bid price requirement
Aug 25Evogen stock rises after unit gets $10M investment from ICL under collaboration agreement
Aug 17Update On Evogene's Subsidiaries: Biomica, Lavie Bio And AgPlenus
Mar 22Evogene: Computational Biology Technology Hub; Focus On Canonic (Medical Cannabis)
Mar 03Evogene's Canonic Begins Selling High THC Cannabis In Israeli Medical Market
Sep 14Evogene: Bullish With Canonic's Entry Into Israeli Medical Cannabis Markets
Jun 16Evogene EPS beats by $0.01, beats on revenue
May 26Evogene unit - Canonic inks cultivation deal for medical cannabis varieties
Dec 23AgPlenus reaches a 'Lead' Stage in its mode-of-action herbicide program
Dec 15Evogene: Q3 Update And Upcoming Catalysts
Nov 30Shareholder Returns
| EVGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.5% | 3.7% | 5.7% |
| 1Y | -69.0% | 29.2% | 36.9% |
Return vs Industry: EVGN underperformed the US Biotechs industry which returned 29.2% over the past year.
Return vs Market: EVGN underperformed the US Market which returned 36.9% over the past year.
Price Volatility
| EVGN volatility | |
|---|---|
| EVGN Average Weekly Movement | 12.4% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: EVGN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: EVGN's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 142 | Ofer Haviv | www.evogene.com |
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
Evogene Ltd. Fundamentals Summary
| EVGN fundamental statistics | |
|---|---|
| Market cap | US$10.41m |
| Earnings (TTM) | -US$19.87m |
| Revenue (TTM) | US$9.45m |
1.0x
P/S Ratio-0.5x
P/E RatioIs EVGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EVGN income statement (TTM) | |
|---|---|
| Revenue | US$9.45m |
| Cost of Revenue | US$1.76m |
| Gross Profit | US$7.69m |
| Other Expenses | US$27.56m |
| Earnings | -US$19.87m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 21, 2024
| Earnings per share (EPS) | -3.70 |
| Gross Margin | 81.42% |
| Net Profit Margin | -210.26% |
| Debt/Equity Ratio | 0% |
How did EVGN perform over the long term?
See historical performance and comparison